BETHESDA, Md.--(BUSINESS WIRE)--Sucampo Pharmaceuticals, Inc., (Nasdaq: SCMP), an emerging pharmaceutical company developing prostone-based therapies for age-related and other diseases, today announced that it has enrolled the first patient in a multi-center Phase 2, dose-finding trial evaluating one of its clinical compounds, cobiprostone (SPI-8811), for the prevention of ulcers and other gastrointestinal injuries in arthritis patients treated with nonsteroidal anti-inflammatory drugs (NSAIDs).
